News & Updates

In patients with psoriatic arthritis (PsA) inadequately controlled by a tumour necrosis factor inhibitor (TNFi), combination treatment with guselkumab plus golimumab appears to yield clinically meaningful benefits only in those with elevated C-reactive protein levels, as shown in a study.

Accelerated biological ageing is associated with increased gout prevalence and incidence and all-cause mortality, according to a study.

In patients with inflammatory arthritis, temporary interruption of biologic or Janus kinase inhibitor (JAKi) therapies during supplemental COVID-19 vaccination does not help improve humoral immunogenicity and even increases flare risk, as shown in the pragmatic COVER trial.

Activin A blockade with garetosmab suppresses heterotopic ossification in adults with the ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP), according to findings from the phase III OPTIMA trial that served as the basis for its Food and Drug Administration (FDA) approval.

Many sonographers in Singapore have work-related musculoskeletal disorders despite good ergonomic awareness, according to a local study.

Patient-reported outcomes among young adults with persistent knee problems after anterior cruciate ligament reconstruction (ACLR) improve with physiotherapist-supervised exercise therapy plus education compared with a single education session and self-directed exercise resource, according to a study.

The American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) Total Improvement Score (TIS) may be used in research autoimmune inflammatory myopathies (AIM), according to a study.

Measurements of rituximab serum concentration are predictive of future drug concentrations associated with early B-cell repopulation in children with inflammatory diseases, suggests a study.

Systemic sclerosis (SSc) patients with positive anti-RNA polymerase III (ARA) prior to autologous haematopoietic cell transplantation (HCT) show a reduced risk of relapse, reveals a study. Moreover, no association has been observed between post-HCT autoantibodies and relapse risk.